Encorafenib is a BRAF kinase inhibitor used in combination with binimetinib to treat unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
I. Basic Information on Encorafenib
1. Mechanism of Action
(1) Encorafenib exerts its antitumor effect by targeting and inhibiting BRAF V600E, wild-type BRAF, and CRAF kinases.
(2) Clinical studies have shown that combination therapy has stronger antiproliferative activity and delayed resistance compared to monotherapy.
2. Indications and Restrictions
(1) Applicable only to patients with BRAF V600E or V600K mutations confirmed by FDA-approved testing methods.
(2) Contraindicated in patients with wild-type BRAF melanoma.
II. Special Populations for Encorafenib Use
1. Women of Childbearing Age
(1) Effective non-hormonal contraception must be used during treatment and for 2 weeks after discontinuation of treatment. (2) Because cannefenib can affect the effectiveness of hormonal contraceptives, alternative contraceptive methods are recommended.
2. Pregnant women
(1) Based on its mechanism of action, it may harm the fetus.
(2) A pregnancy test is required before medication. If pregnancy is suspected during treatment, inform the doctor immediately.
3. Breastfeeding women
Breastfeeding should be completely avoided during treatment and for two weeks after the last dose.
4. Patients with hepatic impairment
No dose adjustment is required for mild hepatic impairment (Child-Pugh A). Individualized dose adjustments are required for patients with moderate to severe hepatic impairment.
5. Patients with renal impairment
No dose adjustment is required for mild to moderate renal impairment. The medication regimen needs to be reassessed for patients with severe renal impairment.
6. Elderly patients
Clinical trial data show no significant difference in safety and efficacy between elderly patients (≥65 years old) and younger patients.
7. Male fertility
Studies suggest that cannefenib may have adverse effects on male fertility.
III. Drug Interactions with Encorafenib
1. CYP3A4 Inhibitors
(1) Avoid co-administration with strong or moderate CYP3A4 inhibitors (such as ketoconazole and itraconazole).
(2) If unavoidable, adjust the encorafenib dosage accordingly.
2. CYP3A4 Inducers
(1) Co-administration with strong or moderate CYP3A4 inducers (such as rifampin) may decrease encorafenib blood concentrations.
(2) It is recommended to completely avoid co-administration with CYP3A4 inducers.
3. Sensitive CYP3A4 Substrates
Co-administration with drugs containing sensitive CYP3A4 substrates may lead to increased toxicity or decreased efficacy.
IV. Precautions with Encorafenib
1. Avoid consuming grapefruit and grapefruit products.
2. Avoid using hormone-containing contraceptives during treatment.
3. Through standardized medication and close monitoring, patients can benefit to the maximum extent from cannefenib treatment while effectively controlling related risks.
